Fundraising FoxSofinnova Ventures — 2019 Investments
5 investments dated 2019 · listed companies and verified rows first · show all
Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.
BiotechDigital HealthHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDonald Notman(Executive Officer)in
Co-investorsAscension VenturesSV Health InvestorsTop Corner CapitalAgent Capital
BiotechLa Jolla, US
Allison E. Hulme(Executive Officer, Director)inRandall E. Woods(Executive Officer, Director)inPeter T. Slover(Executive Officer)Gerald T Proehl(Director)John E Geltosky(Director)Jim E. Heppell(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
InozymeKaruna TherapeuticsVera Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.